ISB News

In Memory of Bill Bowes, Jr.

“To change the way medicine is done. Cheaper and better. Simple as that.”

That was the reason William Ketcham “Bill” Bowes, Jr., cited when asked why he had supported ISB from the beginning and why he had served on ISB’s board of directors for more than a decade. Bill passed away on Dec. 28, 2016, at the age of 90. The ISB community was especially saddened by the news of his death, because Bill’s presence is so vitally woven into ISB’s fabric. In fact, Bill had met and championed Dr. Lee Hood, who then was at Caltech, 20 years before ISB’s founding. He believed in Lee’s “imaginative inventiveness” and invested in the automated protein sequencing device that Lee had developed. The ISB community is forever grateful for Bill’s vision and generosity. He will always be a part of our history.

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.